Omalizumab Treatment in Patients with Severe Allergic Asthma

Omalizumab Treatment in Patients with Severe Allergic Asthma

Introduction:Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthm...

Full description

Bibliographic Details
Main Authors:	Tuğba Songül Tat, Aykut Çilli
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2017-09-01
Series:	İstanbul Medical Journal
Subjects:	Asthma omalizumab severe allergic asthma uncontrolled allergic asthma
Online Access:	http://imj.galenos.com.tr/archives/archive-detail/article-preview/omalizumab-treatment-in-patients-with-severe-aller/20487

Similar Items

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
by: Francesco Menzella, MD, et al.
Published: (2023-06-01)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
by: Carlos A. Torres-Duque, et al.
Published: (2022-11-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
by: Giorgio Walter Canonica, et al.
Published: (2018-11-01)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
by: Tajiri T, et al.
Published: (2023-01-01)

The role of omalizumab in the treatment of adults with severe allergic asthma
by: Sabina Škrgat Kristan
Published: (2013-02-01)

Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
by: Susana Rojo-Tolosa, et al.
Published: (2023-02-01)

Characteristics of Allergic, Eosinophilic, and Overlapping Asthma Phenotypes Among Pediatric Patients with Current Asthma: A Cross-Sectional Study from Saudi Arabia
by: Asseri AA
Published: (2023-12-01)

Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases
by: Baihua Xu, et al.
Published: (2024-04-01)

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
by: Nicola A. Hanania, MD, et al.
Published: (2022-10-01)

Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial
by: Mostafa Ghanei, et al.
Published: (2024-07-01)

Response to Omalizumab as an Add-On Therapy in the Treatment of Allergic Asthma in Adult Chinese Patients—A Retrospective Study
by: Na Li, et al.
Published: (2022-12-01)

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
by: Su N, et al.
Published: (2023-06-01)

Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
by: Weikun Chong, et al.
Published: (2023-10-01)

Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
by: J. Bousquet, et al.
Published: (2008-04-01)

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma—A Romanian Perspective
by: Elena Camelia Berghea, et al.
Published: (2021-12-01)

Well Known and Unknown Asthma Phenotype: Allergic Asthma
by: Ayse Bilge Öztürk, et al.
Published: (2019-07-01)

The Demographic, Clinical and Laboratory Characteristics of Patients with Allergic and Non-allergic Asthma in Van Province
by: Ali Can
Published: (2023-10-01)

Efficacy of ABC-X model care intervention combined with omalizumab on moderate to severe allergic asthma and negative emotional of family members
by: ZHAO Nina, et al.
Published: (2024-06-01)

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy
by: Velling P, et al.
Published: (2011-09-01)

A review of omalizumab for the management of severe asthma
by: Lin CH, et al.
Published: (2016-07-01)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
by: Fatih Uzer, et al.
Published: (2018-05-01)

Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis
by: Arvindran Alaga, et al.
Published: (2023-06-01)

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life
by: Menzella F, et al.
Published: (2022-04-01)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
by: Zafar Zafari, et al.
Published: (2018-01-01)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
by: Pelaia C, et al.
Published: (2021-02-01)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
by: Corrado Pelaia, et al.
Published: (2021-12-01)

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
by: A. Arrobas, et al.
Published: (2021-03-01)

Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation
by: G Norman, et al.
Published: (2013-11-01)

Impact of Direct and Indirect Cat Allergen Exposure Patterns on Allergic Rhinitis and Asthma in Cat-Sensitized Patients
by: Osman Ozan Yegit
Published: (2023-09-01)

Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis
by: C. Incorvaia, et al.
Published: (2016-01-01)

Accreditation of specialized asthma units for adults in Spain: an applicable experience for the management of difficult-to-control asthma
by: Cisneros C, et al.
Published: (2017-05-01)

Allergic and Nonallergic Asthma in Children: Are They Distinct Phenotypes?
by: Seyed Alireza Mahdaviani, et al.
Published: (2014-10-01)

Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma
by: Thomas R. Murphy, et al.
Published: (2022-11-01)

Influence of degree of specific allergic sensitivity on severity of rhinitis and asthma in Chinese allergic patients
by: Zhao Changqing, et al.
Published: (2011-07-01)

Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy
by: Hiroshi Odajima, et al.
Published: (2015-10-01)

Age at asthma diagnosis and onset of symptoms among adults with allergic and non-allergic asthma
by: Johanna Pakkasela, et al.
Published: (2023-01-01)

Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma
by: Daniel P. Henriksen, et al.
Published: (2020-06-01)

The efficiency of flavonols in the setting of experimentally induced allergic asthma
by: Sona Fraková
Published: (2018-06-01)

Antitussive Use in Patients with Inadequately Controlled Moderate-to-Severe Asthma: A Post Hoc Analysis of the Omalizumab EXTRA Trial
by: Rutland CJ, et al.
Published: (2023-06-01)

An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma
by: Gian Luigi Marseglia, et al.
Published: (2024-07-01)